Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 17/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.43 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24195910 | 0.90 | MAP2K1 (0.65) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 | |
| SCHEMBL24195774 | 0.90 | MAP2K1 (0.52) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 | |
| SCHEMBL24195669 | 0.89 | MAP2K1 (0.59) | MAP2K1MAP2K2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL24195794 | 0.89 | MAP2K1 (0.51) | MAP2K1MAP2K2KCNH2 | |
| SCHEMBL24196123 | 0.88 | MAP2K1 (0.54) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 | |
| SCHEMBL24195905 | 0.88 | MAP2K1 (0.50) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 | |
| SCHEMBL24196114 | 0.88 | MAP2K1 (0.67) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 | |
| SCHEMBL23853581 | 0.86 | MAP2K1 (0.68) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 | |
| SCHEMBL31135629 | 0.86 | MAP2K1 (0.68) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 | |
| SCHEMBL24196125 | 0.86 | MAP2K1 (0.55) | MAP2K1PIM1CAMK2BMAP2K2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009887-A1 | CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CUTA, BRAF | MAP2K1 469/4885PIM1 1862/4885CAMK2B 2634/4885 |
| US-11572344-B2 | Cyanoaryl-aniline compounds for treatment of dermal disorders | TYR, CUTA, BRAF | MAP2K1 469/4885PIM1 1862/4885CAMK2B 2634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.